In a lawsuit filed in the US District Court in Maine, Copan alleged that Puritan infringed patents on core flocked swab technology used to collect test samples.
The test is Micronics’ first to receive FDA clearance, and the company is pursuing CE marking for it and the PanNAT system.
Rosetta had disclosed that it intended to file for bankruptcy after its merger with Genoptix was not completed as planned.
The investment bank previously had a Market Perform rating for the company, and it increased the price target on T2 Bio's stock to $12 from $5 per share.
Overall, 20 of the 25 firms in the index saw their share prices grow in May, including seven whose stocks rose more than 20 percent compared to April.
The firm said it will use the funds to commercialize Colvera, its liquid biopsy test for earlier detection of recurrent colorectal cancer.
The new funds, which the company said it will use to develop its Nanotrap Lyme Antigen Test, bring its Series A Round proceeds to a total of $8.5 million.
The companies will jointly offer pathology and molecular testing services to PPD's pharmaceutical and biotechnology customers.
The company is developing tests based on the analysis of the spatial patterns of chromosomes by tagging and imaging their telomeres.
Kurin alleges Magnolia has made false claims about its technology’s false-positive rates and contamination rates, as well as misleading claims about FDA clearance.
The firm will grant underwriters a 30-day option to purchase up to an additional 915,000 shares of its common stock at $7.50 per share.
The French diagnostics firm said it will use the funding to support its merger and acquisition strategy.
The firm reported selling more billable tests in Q1 than any previous quarter and said that it is starting to see momentum in new initiatives, such as carrier screening.
The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.
The firm has not yet priced the shares, but will grant underwriters a 30-day option to purchase up to an additional 847,500 shares in the stock offering.
The merger, which was previously scuttled and later revived with Rosetta shareholder approval, was due to close on May 27.
The $375 million deal marks the integration of Myriad, a leader in the hereditary cancer genetic screening market, with Counsyl, a leader in reproductive genetic screening.
Myriad will merge Counsyl’s reproductive tests with its preventive care business unit into a new business unit called Myriad Women’s Health.
The new funding from Business Finland comes on the heels of a successful financing round announced last week.
BioGx now offers 11 CE-marked infectious disease tests that run on Becton Dickinson's BD Max platform.